CombiMatrix Corp  

(Public, NASDAQ:CBMX)   Watch this stock  
Find more results for CBMX
+0.09 (5.03%)
Real-time:   1:01PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.75 - 1.94
52 week 1.09 - 3.65
Open 1.75
Vol / Avg. 108,004.00/120,588.00
Mkt cap 20.81M
P/E     -
Div/yield     -
EPS -2.27
Shares 11.06M
Beta 0.14
Inst. own 4%
Jan 12, 2015
CombiMatrix Corp at OneMedForum SF
Nov 4, 2014
Q3 2014 CombiMatrix Corp Earnings Call - Webcast
Nov 4, 2014
Q3 2014 CombiMatrix Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -121.97% -61.91%
Operating margin -121.10% -100.44%
EBITD margin - -85.49%
Return on average assets -83.69% -35.82%
Return on average equity -102.73% -180.33%
Employees 43 -
CDP Score - -


IRVINE, CA 92618
United States - Map
+1-949-7530624 (Phone)
+1-949-7534725 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CombiMatrix Corporation is a molecular diagnostics company. The Company operates in the field of genetic analysis and molecular diagnostics through its wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc. located in Irvine, California. The Company operates as a diagnostics reference laboratory, providing DNA-based clinical diagnostic testing services to physicians, hospitals, clinics and other laboratories in the areas of pre-and postnatal development disorders and hematology/oncology genomics. The Company's BAC arrays enable the Company to perform aCGH studies to evaluate genomic alterations. The Company's oligo arrays allow the Company to perform aCGH on a much more refined scale than is possible with BAC technology. During the year ended December 31, 2011, it also owns a 33% interest in Leuchemix, Inc. (Leuchemix), a private drug development company focused on developing a series of compounds to address a number of oncology-related diseases.

Officers and directors

R Judd Jessup Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Mark McDonough President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Scott R. Burell Chief Financial Officer, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
R. Weslie Tyson M.D. Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Scott Gottlieb M.D. Independent Director
Age: 41
Bio & Compensation  - Reuters
Robert E. Hoffman Independent Director
Age: 48
Bio & Compensation  - Reuters
Jeremy M. Jones Independent Director
Age: 72
Bio & Compensation  - Reuters